Lex­i­con 3-for-3 in PhI­II for a new di­a­betes pill, rack­ing up a clean sweep un­der $1.7B Sanofi pact

Lex­i­con Phar­ma­ceu­ti­cals $LXRX is now three-for-three in its Phase III pro­gram for so­tagliflozin, set­ting up reg­u­la­to­ry ap­pli­ca­tions for this Sanofi-part­nered ther­a­py as the first pill to help Type 1 di­a­bet­ics with glycemic con­trol. And it po­si­tions the Texas biotech for its late-stage ef­fort aimed at prov­ing it can do the same for Type 2 di­a­betes.

In­ves­ti­ga­tors test­ed this add-on drug in 1,402 pa­tients with A1C lev­els be­tween 7% and 11%, with a 400 mg dose beat­ing a place­bo in push­ing a sig­nif­i­cant num­ber of pa­tients be­low the 7 mark — the mag­ic num­ber for glycemic con­trol in di­a­betes. But we’ll have to wait for a sci­en­tif­ic con­fer­ence to get the de­tails from in­Tan­dem3.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER